Showing results (81-90 of 107) with videos related to
Sort By:
Pageof 11
Breast Cancer Research and Treatment|December 22, 2011
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialHelen Gogas, Urania Dafni, Maria Karina, et al.American Journal of Cancer Research|January 27, 2017
The fate of BRCA1-related germline mutations in triple-negative breast tumorsVassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, et al.Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.Lung Cancer (Auckland, N.Z.)|September 13, 2021
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in GreeceGiannis Mountzios, Sofia Lampaki, Georgia-Angeliki Koliou, et al.Plos One|December 7, 2018
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) studyAngelos Koutras, Georgios Lazaridis, Georgia-Angeliki Koliou, et al.Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.British Journal of Cancer|May 24, 2022
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 TrialFlora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, et al.Plos One|August 11, 2017
Protein expression patterns of cell cycle regulators in operable breast cancerFlora Zagouri, Vassiliki Kotoula, George Kouvatseas, et al.Pageof 11